Robert F. Kennedy Jr. vows to finalize regulations for greater diverse patient involvement in clinical trials during his ...

The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or ...

Robert F. Kennedy Jr., President Donald Trump's pick to lead the top U.S. health agency, told U.S. senators during his ...

President Donald Trump’s recently issued executive order (EO) putting a stop to diversity, equity, and inclusion programs in the U.S. government is sending ripples far and wide, into areas that some ...

The U.S. Food and Drug Administration has pulled draft guidance from its website requiring companies to test medicines and ...

FDA issued guidance on decentralized elements of clinical trials last fall. Investigators need to balance using decentralized elements and limiting data variability. The COVID-19 pandemic forced ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

"Poor representation in clinical trials reduces our understanding ... It was still accessible on the U.S. government's regulation.gov website. The FDA declined to comment, citing a pause on ...

The guidance would require drug and device makers to set goals and detail their strategies for enrolling people from diverse populations for every late-stage clinical trial slated for U.S ...